Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

Inflammatory Bowel Diseases

Volumn 24, Issue 10, 2018, Pages 2258-2265

  Winthrop, Kevin L ^a   Melmed, Gil Y ^b   Vermeire, Séverine ^c   Long, Millie D ^d   Chan, Gary ^e   Pedersen, Ronald D ^e   Lawendy, Nervin ^e   Thorpe, Andrew J ^e   Nduaka, Chudy I ^e   Su, Chinyu ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

Author keywords

Herpes zoster; Janus kinase; Safety; Shingles; Tofacitinib; Ulcerative colitis

Indexed keywords

JANUS KINASE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; ASIAN; COHORT ANALYSIS; DERMATOME; DRUG EXPOSURE; DRUG SAFETY; ENCEPHALITIS; EVALUATION STUDY; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; TREATMENT FAILURE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VARICELLA ZOSTER VIRUS; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PIPERIDINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; UNITED STATES; YOUNG ADULT;

EID: 85054921937     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy131     Document Type: Article

References (35)

1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30; quiz CE2.
2. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
3. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490-496.
4. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57:1431-1438.
5. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328-2337.
6. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490.
7. Long MD, Martin C, Sandler RS, et al. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420-429.
8. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57:5023-5038.
9. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-in-duced arthritis. J Inflamm (Lond). 2010;7:41.
10. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756-1770.
11. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.
12. Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016;25:991-997.
13. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675-2684.
14. Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302-309.
15. Winthrop KL, Lindsey S, Weinblatt M, et al. Herpes zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib. Arthritis Rheumatol. 2016;68:Abstract 3027.
16. Burmester G, Fitzgerald O, Winthrop K, et al. Integrated safety summary of tofacitinib in psoriatic arthritis clinical studies. Arthritis Rheumatol. 2017;69:Abstract 616.
17. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: the risk of concomitant nonbiologic therapy. Arthritis Rheumatol. 2015;67:Abstract 559.
18. Sandborn WJ, Su C, Sands BE, et al; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-1736.
19. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234-243.
20. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960-1968.
21. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun. 1981;32:24-27.
22. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336-1344.
23. Sadaoka K, Okamoto S, Gomi Y, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis. 2008;198:1327-1333.
24. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790-1798.
25. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253-1262.
26. Nocturne G, Tahmasebi F, Boudaoud S, et al. Tofacitinib is associated with an impaired function of NK cells and a defective immunosurveillance against B-cell lymphomas. Arthritis Rheumatol. 2016;68(Suppl 10):3514.
27. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res. 2004;24:439-454.
28. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011-1021.
29. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 2015;67:731-736.
30. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969-1977.
31. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
32. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-49.
33. US Food and Drug Administration. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for intramuscular injection, highlights of prescribing information. 2017. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581605.pdf. Accessed November 6, 2017.
34. Health Canada. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for injection. 2017. http://ca.gsk.com/media/1350785/patient-information-english.pdf. Accessed November 6, 2017.
35. Lal H, Cunningham AL, Godeaux O, et al; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-2096.